Raymond L H Lam
Overview
Explore the profile of Raymond L H Lam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
95
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Romero-Gomez M, Lawitz E, Shankar R, Chaudhri E, Liu J, Lam R, et al.
J Hepatol
. 2023 Jun;
79(4):888-897.
PMID: 37355043
Background & Aims: This study assessed the effects of the glucagon-like peptide-1 (GLP-1)/glucagon receptor co-agonist efinopegdutide relative to the selective GLP-1 receptor agonist semaglutide on liver fat content (LFC) in...
2.
Jalaludin M, Deeb A, Zeitler P, Garcia R, Newfield R, Samoilova Y, et al.
Pediatr Diabetes
. 2021 Nov;
23(2):183-193.
PMID: 34779103
Objective: To assess the efficacy and safety of sitagliptin in youth with type 2 diabetes (T2D) inadequately controlled with metformin ± insulin. Study Design: Data were pooled from two 54-week,...
3.
Shankar R, Zeitler P, Deeb A, Jalaludin M, Garcia R, Newfield R, et al.
Pediatr Diabetes
. 2021 Nov;
23(2):173-182.
PMID: 34779087
Objective: To assess the efficacy and safety of DPP-4 inhibition with sitagliptin in youth with type 2 diabetes (T2D). Study Design: This was a 54-week, double-blind, randomized, controlled clinical trial...
4.
Raji A, Jin Xu Z, Lam R, ONeill E, Kaufman K, Engel S
Diabetes Ther
. 2020 Aug;
11(10):2419-2428.
PMID: 32852696
Introduction: Older patients with type 2 diabetes (T2D) are at increased risk of diabetic nephropathy and mild renal insufficiency. This analysis compared the anti-hyperglycemic efficacy and safety of sitagliptin with...
5.
Frias J, Zimmer Z, Lam R, Amorin G, Ntabadde C, Iredale C, et al.
Diabetes Obes Metab
. 2019 Jan;
21(5):1128-1135.
PMID: 30609212
Aims: To characterize the glycaemic efficacy and safety of initiation of the dipeptidyl peptidase-4 inhibitor sitagliptin during metformin dose escalation in people with type 2 diabetes (T2D) not at glycated...
6.
Roussel R, Duran-Garcia S, Zhang Y, Shah S, Darmiento C, Shankar R, et al.
Diabetes Obes Metab
. 2018 Nov;
21(4):781-790.
PMID: 30393950
Aims: To compare the effects of continuing versus discontinuing sitagliptin when initiating and intensively titrating insulin glargine. Materials And Methods: Eligible patients had inadequately controlled type 2 diabetes on metformin...
7.
Scott R, Morgan J, Zimmer Z, Lam R, ONeill E, Kaufman K, et al.
Diabetes Obes Metab
. 2018 Jul;
20(12):2876-2884.
PMID: 30019498
Aim: To compare the efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin with the sodium-glucose transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes and mild renal insufficiency. Materials...
8.
Raji A, Long J, Lam R, ONeill E, Engel S
Diabetes Ther
. 2018 Jun;
9(4):1581-1589.
PMID: 29936573
Introduction: To assess the efficacy and safety profile of the dipeptidyl-peptidase-4 inhibitor sitagliptin in a population of self-identified Hispanic/Latino patients with type 2 diabetes. Methods: Data were pooled from ten...
9.
Home P, Lam R, Carofano W, Golm G, Eldor R, Crutchlow M, et al.
Diabetes Obes Metab
. 2018 May;
20(9):2220-2228.
PMID: 29766635
Aim: To compare the efficacy and safety of MK-1293 insulin glargine (Mk-Gla; 100 U/mL) with originator insulin glargine, Lantus (Sa-Gla), in people with type 1 diabetes mellitus (T1DM). Materials And...
10.
Hollander P, Carofano W, Lam R, Golm G, Eldor R, Crutchlow M, et al.
Diabetes Obes Metab
. 2018 May;
20(9):2229-2237.
PMID: 29761615
Aim: To compare the efficacy and safety of MK-1293 insulin glargine (Mk-Gla) and Lantus (Sa-Gla) in people with type 2 diabetes mellitus (T2DM). Materials And Methods: This Phase 3, randomized,...